Every Form 4 that Zimmer Biomet Holdings, Inc. (ZBH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZBH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZBH filings page.
Zimmer Biomet Holdings executive Yi Sang reported an equity award vesting and conversion. On February 25, 2026, 2,785 restricted stock units were exercised and converted into 2,785 shares of common stock at a stated price of $0.00 per share.
Following these transactions, Yi Sang directly held 5,567 restricted stock units and 22,837 shares of common stock. According to the vesting schedule, one-third of the RSUs vested on February 25, 2026, with the remaining units vesting one-half on each of February 25, 2027 and February 25, 2028.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported equity transactions tied to restricted stock units. On February 25, 2026, 2,347 RSUs were exercised into 2,347 shares of common stock at $0.00 per share as part of an RSU vesting event. A footnote explains that one-third of the RSUs vested on that date, with the remainder vesting in equal parts on February 25, 2027 and February 25, 2028. To cover tax withholding on the vesting, 924 shares of common stock were withheld by the company at a reference price of $99.51 per share. After these transactions, Winkler directly held 9,418 shares of common stock and 4,693 RSUs.
Zimmer Biomet Holdings' Executive VP and CFO Suketu Upadhyay reported equity award activity involving restricted stock units and common shares. On February 25, 2026, he exercised 6,364 restricted stock units, converting them into 6,364 shares of common stock at a stated price of $0.0000 per share. Following this conversion, his direct holdings increased to 64,117 shares of common stock and 12,726 restricted stock units. On the same date, 2,832 common shares at $99.51 per share were withheld by the company to satisfy tax withholding obligations linked to the RSU vesting, rather than an open-market sale.
Zimmer Biomet Holdings Chairman, President and CEO Ivan Tornos reported equity award activity involving restricted stock units and common shares of ZBH. He exercised or converted 19,090 restricted stock units into 19,090 shares of common stock at a price of $0.0000 per share. To cover tax withholding on the RSU vesting, 10,557 common shares were withheld by the company at a price of $99.5100 per share, as described in the footnotes. Following these transactions on February 25, 2026, his directly held common stock position was 67,682 shares, and 38,179 restricted stock units remained outstanding, with one-third vesting on February 25, 2026 and the balance vesting in equal installments on February 25, 2027 and February 25, 2028.
Zimmer Biomet Holdings officer Paul A. Stellato reported equity compensation activity involving restricted stock units (RSUs) and common shares. On February 25, 2026, 820 RSUs were exercised and converted into 820 shares of common stock at a stated price of $0.0000 per share.
On the same date, 402 common shares were withheld at $99.5100 per share to cover tax withholding obligations related to the RSU vesting, as described in the footnotes. One-third of the RSUs vested on February 25, 2026, with the remaining RSUs scheduled to vest one-half on each of February 25, 2027 and February 25, 2028.
Following these transactions, Stellato directly held 1,638 RSUs and 4,527 shares of common stock. The disposition was for tax withholding rather than an open-market sale.
Noor Jehanzeb reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. reported that officer Noor Jehanzeb received a grant of 10,076 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock. The award vests annually over three years in one-third increments starting on February 20, 2027.
ZIMMER BIOMET HOLDINGS, INC. officer Chad F. Phipps reported equity compensation and related share movements. On February 20, 2026, 2,246 restricted stock units were exercised into 2,246 shares of common stock at a price of $0.00 per share.
He was also granted 9,818 new restricted stock units, each representing a right to receive one common share, vesting annually over three years in one‑third installments starting February 20, 2027. To satisfy tax withholding on the RSU vesting, 942 common shares were disposed of at $98.62 per share through company share withholding, leaving him with 62,137 directly held common shares.
Thornal Kevin R reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. reported that executive Kevin R. Thornal, Group President–Global Business, received a grant of 27,385 restricted stock units (RSUs) on February 20, 2026. Each RSU represents a contingent right to receive one share of common stock and vests in three equal annual installments starting February 20, 2027.
Zimmer Biomet Holdings executive Yi Sang reported equity awards and conversions, increasing his direct holdings through stock-based compensation. He acquired 2,382 shares of common stock on February 20, 2026 via exercise or conversion of restricted stock units (RSUs) at $0.00 per share, bringing his direct common stock ownership to 20,052 shares.
On the same date, he also acquired 2,382 RSUs through an exercise or conversion and received a new grant of 9,043 RSUs. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and vests annually over three years in one-third increments starting on February 20, 2027.
Zimmer Biomet Group Pres, EMEA Wilfred Van Zuilen reported equity compensation activity. On February 20, 2026, 2,451 restricted stock units vested into the same number of common shares, and 638 shares were withheld to cover tax obligations. He also received a new award of 10,334 restricted stock units that vest annually over three years starting February 20, 2027. After these transactions, he directly holds 12,784 restricted stock units and 23,455 shares of common stock.
Zimmer Biomet Holdings, Inc. senior vice president and chief human resources officer Lori Winkler reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 20, 2026, 1,845 RSUs were converted into 1,845 shares of common stock, and she received a new grant of 7,880 RSUs. According to the disclosure, each RSU represents a contingent right to receive one share of company common stock, and the new grant vests annually over three years in one-third increments starting February 20, 2027. The filing also shows 683 shares of common stock were withheld by the company at $98.62 per share to satisfy tax withholding obligations related to the RSU vesting.
Zimmer Biomet Holdings, Inc. reported that VP, Controller and Chief Accounting Officer Paul A. Stellato received new equity awards and related share movements. On February 20, 2026, he acquired 701 restricted stock units (RSUs) through an exercise or conversion and received additional RSU grants of 2,842 and 4,651 units at no cost. Each RSU represents a contingent right to one share of common stock, with one grant vesting annually over three years starting February 20, 2027, and the other vesting in full on February 20, 2028.
The 701 RSUs were converted into 701 shares of common stock, increasing his direct common stock holdings before tax withholding. To cover tax obligations on the RSU vesting, 362 common shares were withheld by the company at a price of $98.62 per share, leaving him with 4,109 common shares directly held, which includes 60 shares previously acquired under the Employee Stock Purchase Plan.
Zimmer Biomet Holdings, Inc. Chairman, President and CEO Ivan Tornos reported equity award and related share movements. He acquired 15,996 shares of common stock through the exercise of restricted stock units and received a new grant of 65,103 restricted stock units, each representing one future share of common stock.
To cover tax withholding on the RSU vesting, 8,846 common shares were withheld by the company at a price of $98.62 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, Tornos directly owned 59,149 shares of common stock, which include 246 shares acquired under the Employee Stock Purchase Plan, and 65,103 restricted stock units that vest in three equal annual installments starting February 20, 2027.
Zimmer Biomet Holdings, Inc. executive vice president and CFO Suketu Upadhyay reported equity compensation activity involving restricted stock units (RSUs) and common stock. He received a grant of 21,701 RSUs, each representing a contingent right to one share of Zimmer Biomet common stock, vesting annually over three years in one-third increments starting February 20, 2027.
On the same date, 5,445 RSUs were converted into 5,445 shares of common stock through an exercise or conversion transaction. Of those shares, 2,446 were withheld by the company at a price of $98.62 per share to satisfy tax withholding obligations tied to the RSU vesting. Following these transactions, Upadhyay directly owned 57,753 shares of common stock.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported an equity compensation award tied to past performance. She acquired 3,935 performance-based restricted stock units, each representing one share of common stock, following a determination on February 19, 2026 of results for the 2023–2025 performance period. These 3,935 RSUs will vest on March 6, 2026, subject to the award’s terms.
Zimmer Biomet Holdings reported that Group President, EMEA, Wilfred Van Zuilen acquired 4,843 restricted stock units (RSUs) as an equity award. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock. These RSUs were earned based on performance for the 2023–2025 period, as determined on February 19, 2026, and are scheduled to vest on March 6, 2026.
ZIMMER BIOMET HOLDINGS, INC. executive vice president and CFO Suketu Upadhyay reported an acquisition of 10,217 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock at no purchase price.
The RSUs were originally granted as performance-based awards on March 6, 2023, with results tied to a performance period covering 2023 to 2025. Based on actual performance determined on February 19, 2026, 10,217 RSUs were earned and are scheduled to vest on March 6, 2026, if vesting conditions are satisfied.
ZIMMER BIOMET HOLDINGS, INC. reported that executive Paul A. Stellato, its VP, Controller and Chief Accounting Officer, acquired 1,363 restricted stock units as part of a performance-based equity award. These RSUs were earned based on performance for the 2023–2025 period and are scheduled to vest on March 6, 2026.
Zimmer Biomet Holdings senior vice president and chief legal officer Chad F. Phipps reported an equity award tied to past performance. He acquired 4,692 restricted stock units as of February 19, 2026, at a stated price of $0.00 per unit. These RSUs were earned under a performance-based grant covering the 2023–2025 period and are scheduled to vest on March 6, 2026. Each RSU represents the right to receive one share of Zimmer Biomet common stock.
Zimmer Biomet Holdings reported that Group President, Asia Pacific, Yi Sang acquired 7,050 restricted stock units (RSUs) at a price of $0.00 per unit. These RSUs were earned from performance-based awards granted in March and September 2023 for the 2023–2025 performance period.
Based on actual performance determined on February 19, 2026, Yi Sang earned 5,298 RSUs from the March 2023 grant and 1,752 RSUs from the September 2023 grant. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and the 7,050 RSUs will vest on March 6, 2026.
ZIMMER BIOMET HOLDINGS, INC. Chairman, President and CEO Ivan Tornos reported an acquisition of 24,436 restricted stock units (RSUs) tied to prior performance-based awards. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock at no purchase price.
The RSUs relate to performance-based grants awarded in March and September 2023 for a 2023–2025 performance period. Based on actual performance determined on February 19, 2026, he earned 12,184 RSUs from the March grant and 12,252 RSUs from the September grant, which together will vest on March 6, 2026 if conditions are satisfied.
Yi Sang reported open-market sale transactions in a Form 4 filing for ZBH. The filing lists transactions totaling 1,000 shares at a weighted average price of $96.49 per share. Following the reported transactions, holdings were 17,670 shares.
Zimmer Biomet Holdings, Inc. director Louis Shapiro reported a routine equity-related transaction involving deferred compensation. On 12/31/2025, he acquired 152.22 phantom stock units tied to Zimmer Biomet common stock under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is convertible into one share of common stock, and the units are scheduled to be settled in company shares within sixty days after he ceases serving as a director. Following this transaction, he beneficially owned 2,500.354 phantom stock units, which includes 5.625 units previously accrued on 10/31/2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Arthur J. Higgins reported changes in his deferred compensation holdings. On 12/31/2025 he acquired 304.439 phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors, which are tied 1-for-1 to shares of common stock. These units are scheduled to be settled in cash in ten annual installments after his service as a director ends, beginning within sixty days after the end of the calendar year in which his board service ceases.
Following this transaction, Higgins beneficially owned 35,967.099 phantom stock units. This total includes 85.437 phantom stock units that were previously accrued on October 31, 2025 under the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Theresa Maria Hilado reported a change in her deferred compensation holdings tied to company stock. On 12/31/2025 she acquired 373.63 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors at a 1-for-1 conversion rate with common stock. Following this transaction, she beneficially owned 11,275.465 phantom stock units.
The phantom stock units are to be settled in cash in ten annual installments, beginning within sixty days after the end of the calendar year in which her service as a director ends. The reported balance includes 26.117 phantom units accrued on 10/31/2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Devdatt Kurdikar reported an equity-related transaction on 12/31/2025 under a deferred compensation arrangement. The filing shows the acquisition of 152.22 phantom stock units at a listed conversion or exercise price of $90.33, bringing his total directly held phantom stock units to 1,769.983.
The units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and are designed to be settled in shares of Zimmer Biomet common stock on a 1-for-1 basis within sixty days after he ceases serving as a director. The total includes 3.876 phantom stock units that were added on October 31, 2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings director reports phantom stock unit grant. On 12/31/2025, a company director acquired 172.977 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. These units are tied 1-for-1 to shares of Zimmer Biomet common stock and are scheduled to be settled in company shares within sixty days after the director’s service on the board ends. Following this transaction, the director beneficially owned a total of 5,579.523 phantom stock units, which includes 12.952 units accrued on 10/31/2025 through the plan’s dividend reinvestment feature.
Zimmer Biomet Holdings, Inc. reported a director-level deferred compensation transaction involving phantom stock units. On 12/31/2025, a director acquired 304.439 phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors at a 1-for-1 ratio with common stock.
After this transaction, the director beneficially owned 31,586.952 phantom stock units in total. These units are to be settled in cash in five annual installments, beginning within sixty days after the end of the calendar year in which the director’s service on the board ends. The total includes 74.943 phantom stock units that were accrued on 10/31/2025 through the plan’s dividend reinvestment feature.
Zimmer Biomet Holdings, Inc. director Michael J. Farrell reported a deferred compensation transaction involving phantom stock units as of 12/31/2025. He acquired 415.144 phantom stock units tied to Zimmer Biomet common stock under the company's Deferred Compensation Plan for Non-Employee Directors at a stated conversion rate of 1-for-1. Each unit represents the economic value of one share, but the units are to be settled in cash, in a lump sum, within sixty days after he ceases serving as a director. Following this transaction, he holds 17,775.682 phantom stock units directly, which includes 41.590 units that were previously accrued on 10/31/2025 through the plan’s dividend reinvestment feature.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported routine equity compensation activity involving restricted stock units (RSUs) tied to the company’s common stock. On 11/28/2025, RSUs covering 56.534 shares and 122.695 shares were settled into common stock at an exercise price of $0 per share, reflecting previously granted awards becoming deliverable. On the same date, 56.534 shares and 122.695 shares of common stock were withheld at a price of $97.52 per share to cover FICA and related tax obligations associated with her retirement eligibility under the terms of those awards. Following these transactions, she directly holds 6,833 shares of common stock, along with remaining RSUs that vest on March 6, 2026, and in two tranches on February 20, 2026 and February 20, 2027.
Zimmer Biomet Holdings (ZBH) reported an insider equity transaction by its Exec VP & CFO, Suketu Upadhyay. On November 10, 2025, 10,632 performance-based RSUs vested and were converted into common stock at $0 per share. To cover taxes, 4,731 shares were withheld at a price of $87.73 per share.
Following these transactions, the executive’s directly held common stock totaled 54,754 shares. The filing notes these RSUs each represented the right to receive one share of common stock, and the earned performance-based RSUs vested on November 10, 2025.
Zimmer Biomet Holdings (ZBH) reported an insider equity award on a Form 4. The company’s Executive Vice President and CFO received 10,632 restricted stock units (RSUs), recorded as an acquisition at $0 per unit and held directly.
The RSUs were part of a performance-based grant made on September 1, 2023, with results measured over October 1, 2024 to September 30, 2025. On October 24, 2025, the final outcome was determined, and 10,632 RSUs were earned. Each RSU represents the right to receive one share of Zimmer Biomet common stock. The earned RSUs are scheduled to vest on November 10, 2025.